Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat.
Conditions
Interventions
CBL-514 Injection
0.9% Sodium Chloride
Locations
14
United States
Investigational Site 1
Encinitas, California, United States
Investigational site 2
Aventura, Florida, United States
Investigational Site 3
Alpharetta, Georgia, United States
Investigational Site 4
Hunt Valley, Maryland, United States
Investigational site 5
Omaha, Nebraska, United States
Investigational site 6
New York, New York, United States
Start Date
October 1, 2026
Primary Completion Date
August 1, 2027
Completion Date
October 1, 2027
Last Updated
April 14, 2026
NCT07140939
NCT05760248
NCT05736107
NCT05155683
NCT03871556
NCT04090853
Lead Sponsor
Caliway Biopharmaceuticals Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions